TLDR: The global market for AI Medical Image Reading Assistant Systems is set for significant expansion, with projections indicating a rise from US$ 5.73 billion in 2024 to US$ 30.7 billion by 2031, demonstrating a robust compound annual growth rate (CAGR) of 27.1%. This growth is driven by the increasing adoption of AI in radiology for early disease screening, risk assessment, and precision diagnosis across various medical domains.
The global market for AI Medical Image Reading Assistant Systems is on the cusp of explosive growth, according to a recent report by QYResearch. The market is projected to surge from US$ 5.73 billion in 2024 to an impressive US$ 30.7 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 27.1% during the forecast period from 2025 to 2031. This remarkable expansion underscores the transformative impact of AI-powered diagnostic systems on modern radiology workflows.
These advanced systems are revolutionizing healthcare by significantly enhancing capabilities in early disease screening, comprehensive risk assessment, and highly precise diagnosis. The escalating demand for such technologies is evident across a multitude of medical specialties, including oncology, neurology, pulmonary, and musculoskeletal domains. Both developed and emerging healthcare markets are accelerating their adoption of these AI solutions.
Key players dominating the AI medical image reading landscape include industry giants such as Siemens Healthineers, GE HealthCare, Philips Healthcare, Canon Medical Systems, Fujifilm Healthcare, Hitachi Healthcare, and Samsung Medison. Specialized AI companies like Aidoc, Lunit, Arterys, VUNO, Deepwise Healthcare, and InferVision are also making significant strides. Furthermore, major tech companies like Google Health, IBM Watson Health, Microsoft Cloud for Healthcare, Tencent Healthcare, and Alibaba Health are actively contributing to this evolving market.
Recent developments highlight the rapid innovation within this sector. In 2025, Aidoc launched its upgraded aiOS platform across 22 sites in collaboration with Advocate Health, providing real-time triage and diagnostic support. Similarly, Lunit expanded its AI chest screening solutions in Southeast Asia, while Deepwise initiated large-scale deployments in Chinese tertiary hospitals.
The regulatory environment is also evolving to support this growth. As of mid-2025, over 1,000 AI/ML-enabled medical imaging tools have received regulatory clearance, predominantly utilizing traditional machine learning, with a growing emphasis on generative and explainable AI systems. This regulatory clarity, particularly under frameworks like the EU AI Act effective in 2024, is fostering market momentum.
Also Read:
- Generative AI Revolutionizes Agriculture: Market Poised for Significant Growth
- AI’s Transformative Impact: Industrial Automation Market Set to Skyrocket to $111.8 Billion by 2034
Geographically, Asia-Pacific and North America are leading the market expansion, propelled by national healthcare digitization policies and mandates for AI integration. Europe is also gaining traction, benefiting from clearer regulatory guidelines. Projections for 2031 indicate strong growth in key countries such as the U.S., China, Japan, South Korea, India, Germany, and the UK. The market’s long-term transformation is driven by rapid algorithmic advancements, increasing clinical demand, and supportive regulatory frameworks.
